Food and Drug Administration (FDA) Funding This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Join Us for the 20th Anniversary of the HHS SBIR/STTR Conference in Dallas, TX!
WHEN: Tuesday, October 30 – Thursday, November 1 WHERE: Hilton Anatole, 2201 N. Stemmons Freeway, Dallas, TX 75207 WEBSITE: www.hhs20dallas.org This dynamic, national, three-day event is designed to educate attendees about America’s Largest Seed Fund and how to access federal resources, develop competitive proposals, and secure awards. At $1 billion dollars of annual HHS funding, this is one of the largest sources of early-stage capital for life science technology commercialization in the United States. Hosted by the Dallas Regional Chamber, A Better Tomorrow: Big Ideas in BioTech will be relevant to a divers...
Source: NIH Extramural Nexus - September 26, 2018 Category: Research Authors: NIH Staff Tags: Other NIH Happenings SBIR STTR Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) (U44 - Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-18-035 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U44) applications to support small business research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical iss...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 1, 2018 Category: Research Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) (UT2 - Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-18-033 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (UT2) applications to support small business research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical iss...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 1, 2018 Category: Research Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-HL-18-031 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite exploratory/developmental phased award cooperative agreement (UG3/UH3) applications to support investigator-initiated clinical trials (Phase I or later phase) aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 1, 2018 Category: Research Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-18-030 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 1, 2018 Category: Research Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas ...
Source: NIDDK Funding Opportunities - August 1, 2018 Category: Endocrinology Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite exploratory/developmental phased award cooperative agreement (UG3/UH3) applications to support investigator-initiated clinical trials (Phase I or later phase) aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that use RM products with demons...
Source: NIDDK Funding Opportunities - August 1, 2018 Category: Endocrinology Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) (UT2 - Clinical Trial Not Allowed)
The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (UT2) applications to support small business research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may...
Source: NIDDK Funding Opportunities - August 1, 2018 Category: Endocrinology Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) (U44 - Clinical Trial Not Allowed)
The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U44) applications to support small business research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may...
Source: NIDDK Funding Opportunities - August 1, 2018 Category: Endocrinology Source Type: funding

Minor Use Minor Species Development of Drugs (R01)
Funding Opportunity PAR-18-827 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop, or support the development of new animal drugs intended for minor use in major species or for use in minor species. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 11, 2018 Category: Research Source Type: funding

Cooperative Agreement to Support the Food and Agriculture Organization (FAO) (U01)
Funding Opportunity RFA-FD-18-009 from the NIH Guide for Grants and Contracts. The Food and Drug Administration (FDA) is announcing its intention to receive and consider a single source application for award of a cooperative agreement in fiscal year 2018 (FY 2018) to the Food and Agriculture Organization (FAO) of the United Nations to support global strategies that address food safety, nutrition and public health. The purpose of this cooperative agreement is to: 1. Utilize FAO's extensive research and expertise on country development and aid activities. 2. Contribute to the research, knowledge base and development of fo...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 20, 2018 Category: Research Source Type: funding

Improving Access to Overdose Treatment
Grants to expand access to Food and Drug Administration approved drugs and/or devices for emergency treatment of known or suspected opioid overdose. Geographic coverage: Nationwide -- Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - April 9, 2018 Category: American Health Source Type: funding

Assuring Radiation Protection (U18)
Funding Opportunity RFA-FD-18-021 from the NIH Guide for Grants and Contracts. Food and Drug Administration/ Center for Devices and Radiological (CDRH) is announcing its intention to accept and consider a single source application for the award of a cooperative agreement in fiscal year 2018 to Conference of Radiation Control Program Directors, Inc. (CRCPD) in support of coordination of Federal and State actions to assure radiation protection of the American public. The primary purpose of this cooperative agreement is to assist CRCPD members (State radiation control programs) in their efforts to protect the public, radia...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 23, 2018 Category: Research Source Type: funding

Make Your Voice Heard! We want Your Ideas to Reduce Administrative Burden in Research with Laboratory Animals
NIH has, for many years, been concerned about the increasing burden of applying for, reporting on, and the costs faced by researchers when complying with requirements on federally-funded research grants— so much so that it is even called out in our strategic plan as an area to address. Today, as we continue to implement the 21st Century Cures Act, NIH is requesting public feedback on some proposed approaches to reduce administrative burden on investigators use of laboratory animals in biomedical research (NOT-OD-18-152 and Federal Register Notice 2018-05173). Together with our colleagues at the U.S. Department of Agric...
Source: NIH Extramural Nexus - March 15, 2018 Category: Research Authors: Mike Lauer Tags: blog Open Mike Administrative Burden Animal Welfare Request For Information (RFI) Source Type: funding

National Laboratory Curriculum Framework Development
Funding Opportunity RFA-FD-18-005 from the NIH Guide for Grants and Contracts. The Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA), Office of Training Education and Development (OTED) is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement Grant. The goals of this Cooperative Agreement Grant are to continue the development of the Integrated Food Safety System (IFSS) National Curriculum Standard (NCS) for the laboratory competency and curriculum frameworks, further work on the development and validation of competency statements. As the NCS is completed at each level, ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 15, 2018 Category: Research Source Type: funding